SynthesisFrontiers in pharmacology2026
The "efficacy window" phenomenon of daridorexant in insomnia treatment: a dose-dependent time-course meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to comprehensively analyze and evaluate the efficacy and safety of daridorexant in treating insomnia. Methods: This study conducted a systematic search across 7 electronic databases: PubMed, Web of Science, Cochrane Library, Embase, ClinicalTrials.gov, Scopus and the World Health Organization International Clinical Trials Registry Platform [http://www.who.int/ictrp/search/en/]). The review was registered (CRD420251174557). The effectiveness indicators included objective measures such as latency to persistent sleep (LPS) and wake time after sleep onset (WASO), as well as subjective measures including subjective latency to sleep onset (sLSO), subjective total sleep time (sTST), Visual analog scale (VAS), the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) sleepiness domain score, and insomnia severity index (ISI). The safety indicators encompassed treatment-emergent adverse events (TEAEs), adverse events leading to premature termination, severe adverse events (SAEs), and adverse events of special interest (AESIs). Results: This study included a total of 5 articles, 6 RCTs, with a total of 2905 patients with insomnia. In terms of objective indicators, during the initial treatment stage (1-2 days), daridorexant was superior to the placebo; this advantage persisted at 1 month; and at 3 months, the 25 mg dose remained effective. In terms of subjective indicators, at 1 month, Daridorexant outperformed the placebo in most of the indicators; at 3 months, the 25 mg dose remained effective in sTST (SMD 0.25 [0.14, 0.36], Conclusion: The efficacy of daridorexant in the treatment of insomnia is dose-dependent, with doses of 25 mg and 50 mg demonstrating significant improvements in both subjective and objective sleep metrics in the short term (1 month). Notably, the efficacy of the 25 mg dose is sustained in objective metrics over the medium term (3 months). Daridorexant overall performance is relatively safe, but the 25 mg dose may be associated with an increased risk of AESIs. Systematic Review Registration: Identifier, CRD420251174557.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.